The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Published version of a preprint
Abstract
Chemotherapy and radiation are more effective in wild-type (WT) p53 tumors due to p53 activation. This is one rationale for developing drugs that reactivate mutant p53 to synergize with chemotherapy and radiation. Zinc metallochaperones (ZMC) are a new class of mutant p53 reactivators that restore WT structure and function to zinc-deficient p53 mutants. We hypothesized that the thiosemicarbazone, ZMC1, would synergize with chemotherapy and radiation. Surprisingly, this was not found. We explored the mechanism of this and found the reactive oxygen species (ROS) activity of ZMC1 negates the signal on p53 that is generated with chemotherapy and radiation. We hypothesized that a zinc scaffold generating less ROS would synergize with chemotherapy and radiation. The ROS effect of ZMC1 is generated by its chelation of redox active copper. ZMC1 copper binding (KCu) studies reveal its affinity for copper is approximately 108 greater than Zn2+. We identified an alternative zinc scaffold (nitrilotriacetic acid) and synthesized derivatives to improve cell permeability. These compounds bind zinc in the same range as ZMC1 but bound copper much less avidly (106- to 107-fold lower) and induced less ROS. These compounds were synergistic with chemotherapy and radiation by inducing p53 signaling events on mutant p53. We explored other combinations with ZMC1 based on its mechanism of action and demonstrate that ZMC1 is synergistic with MDM2 antagonists, BCL2 antagonists, and molecules that deplete cellular reducing agents. We have identified an optimal Cu2+:Zn2+ binding ratio to facilitate development of ZMCs as chemotherapy and radiation sensitizers. Although ZMC1 is not synergistic with chemotherapy and radiation, it is synergistic with a number of other targeted agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, ZMC1 can chelate redox-active copper,447 increase intracellular reactive oxygen levels and decrease glutathione concentrations to exert antitumor effects.441,444”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [447]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007
Regulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752
NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity
Pink, J. J., Planchon, S. M., Tagliarino, C., Varnes, M. E., Siegel, D., & Boothman, D. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5416 · Cited by 376
Self-citationPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Research works printed but not linked: 27
- Lowe, 1994, p53 status and the efficacy of cancer therapy in vivo, Science, 266, 807, 10.1126/science.7973635 · DOI · Paper page
- Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 · DOI · Paper page
- Barbieri, 2006, MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death, Mol Cancer Ther, 5, 2358, 10.1158/1535-7163.MCT-06-0305 · DOI
- Coll-Mulet, 2006, MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells, Blood, 107, 4109, 10.1182/blood-2005-08-3273 · DOI · Paper page
- Blanden, 2015, Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore, Mol Pharmacol, 87, 825, 10.1124/mol.114.097550 · DOI · Paper page
- Yu, 2018, Zinc metallochaperones reactivate mutant p53 using an ON/OFF switch mechanism: a new paradigm in cancer therapeutics, Clin Cancer Res, 24, 4505, 10.1158/1078-0432.CCR-18-0822 · DOI
- Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
- Blanden, 2015, Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer, Drug Discov Today, 20, 1391, 10.1016/j.drudis.2015.07.006 · DOI
- Yu, 2017, Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53, Mol Pharmacol, 91, 567, 10.1124/mol.116.107409 · DOI · Paper page
- Meek, 2009, Posttranslational modification of p53: cooperative integrators of function, Cold Spring Harbor Perspect Biol, 1, a000950, 10.1101/cshperspect.a000950 · DOI · Paper page
- Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- Zhang, 2011, Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect, Proc Natl Acad Sci U S A, 108, 16259, 10.1073/pnas.1113884108 · DOI · Paper page
- Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 58, 621, 10.1124/pr.58.3.10 · DOI · Paper page
- Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4 · DOI · Paper page
- Franken, 2006, Clonogenic assay of cells in vitro, Nat Protoc, 1, 2315, 10.1038/nprot.2006.339 · DOI · Paper page
- Shimada, 2018, Copper-binding small molecule induces oxidative stress and cell-cycle arrest in glioblastoma-patient-derived cells, Cell Chem Biol, 25, 585, 10.1016/j.chembiol.2018.02.010 · DOI
- Kocyla, 2017, Molar absorption coefficients and stability constants of Zincon metal complexes for determination of metal ions and bioinorganic applications, J Inorg Biochem, 176, 53, 10.1016/j.jinorgbio.2017.08.006 · DOI
- Kim, 2002, Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities, J Med Chem, 45, 3905, 10.1021/jm0201520 · DOI
- Smith, 1989, Critical stability constants, 10.1007/978-1-4615-6764-6 · DOI · Paper page
- Li, 2011, Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy, Clin Cancer Res, 17, 275, 10.1158/1078-0432.CCR-10-1983 · DOI
- Kohler, 1970, Inhibition of NADP dependent oxidoreductases by the 6-aminonicotinamide analogue of NADP, FEBS Lett, 6, 225, 10.1016/0014-5793(70)80063-1 · DOI · Paper page
- Tedeschi, 2015, Suppression of cytosolic NADPH pool by thionicotinamide increases oxidative stress and synergizes with chemotherapy, Mol Pharmacol, 88, 720, 10.1124/mol.114.096727 · DOI
- Hockenbery, 1993, Bcl-2 functions in an antioxidant pathway to prevent apoptosis, Cell, 75, 241, 10.1016/0092-8674(93)80066-N · DOI · Paper page
- Souers, 2013, ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, 19, 202, 10.1038/nm.3048 · DOI · Paper page
- Margalit, 2012, Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function, Int J Cancer, 131, E562, 10.1002/ijc.26441 · DOI
- Puca, 2009, Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc, Exp Cell Res, 315, 67, 10.1016/j.yexcr.2008.10.018 · DOI
- Ni Chonghaile, 2011, Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy, Science, 334, 1129, 10.1126/science.1206727 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
Metadata
- Authors
- Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., Loh, S. N., Kimball, S. D., & Carpizo, D. R.
- Affiliations
- 1Department of Molecular Biology, Rutgers University, Piscataway, New Jersey.
- 2Program of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.
- 4Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey.
- 5Department of Biochemistry and Molecular Biology, SUNY Upstate Medical University, Syracuse, New York.
- 6Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
- ORCID
- Gilleran, John
- Venue
- Molecular Cancer Therapeutics
- Published
- 2019-08-01
- Volume
- 18
- Issue
- 8
- Pages
- 1355-1365
- ISSN
- 1535-7163
- 1538-8514
- Cited by
- 35
- References
- 5
- Language
- en
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R01 CA200800, K08 CA172676)
- Breast Cancer Research FoundationBreast Cancer Research Foundation (BCRF)
- HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (F30 GM113299)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-1080
- The paper
- Zaman, S., Yu, X., Bencivenga, A. F., Blanden, A. R., Liu, Y., Withers, T., Na, B., Blayney, A. J., Gilleran, J., Boothman, D. A., Loh, S. N., Kimball, S. D., & Carpizo, D. R. (2019). Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-1080
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.